Back

The Flawed Math Behind Modern Clinical Trials

What if the mathematical foundations of our clinical trials are fundamentally broken—and no amount of clever design can fix them? For decades, researchers have relied on "crossover" trials, where patients receive different treatments in a specific sequence, to save time and money. However, a new analysis reveals that a popular shortcut used to crunch this data is not just flawed, but "completely inadequate."

The Culprit: The "Two-Stage" Analysis Habit

This discovery targets a specific statistical habit pervasive in these trials.
In the two-stage process, researchers:

1. First test for a "carryover effect"—essentially checking if the first drug is still lingering in a patient’s system.
2. If they find no evidence of carryover, they proceed with a simplified model to measure the drug’s effectiveness.

For the average patient or doctor reading a study, this might seem like a technicality. But in reality, it is a mathematical trap.

The Statistical Failure

When researchers use this two-stage method, the resulting confidence intervals—the range where we expect the "truth" to lie—become dangerously unreliable. This bias is introduced by the "logical flaw" of choosing a mathematical model based on the results of a previous test.

A Closer Look at the Study

This study, led by P. Kabaila and M. Vicendese, focused on the theoretically superior high-order ABAB/BABA design.
While designed to separate patient variation from carryover effects, the team found that the two-stage analysis itself introduces massive bias.

Sobering Data & Key Findings

The Core Problem: For a study aiming for a 95% confidence level (the scientific gold standard), the two-stage procedure frequently collapsed.

• Researchers found a minimum coverage probability of 0.4711.
• In plain English: A trial that claims to be 95% certain may actually be closer to 47% certain.
• This statistical failure occurs precisely when the carryover effect is small but non-zero—too small for the preliminary test to catch, but large enough to poison the final results.
• The bias persisted even with increasing sample sizes and was not caused by a lack of data.

Limits and Caveats of the Analysis

It is important to note the study's boundaries, which define where its conclusions are most applicable.

Key Assumptions & Parameters

The team's analysis operated under specific conditions:

• They assumed the error variance was known.
• The focus was on "first-order" carryover, where only the immediate following treatment period is affected.
• They noted that using a more honest, carryover-unbiased estimator is only beneficial when patient variation is high enough—specifically when $\sigma^2_s \geq 4.5\sigma^2_\varepsilon$.

The Conclusion: A Stern Warning

Ultimately, this study serves as a stern warning to the medical community: complexity in trial design cannot outrun a flawed analysis. To maintain the integrity of clinical results, the two-stage procedure must be abandoned.

---

Based on: Kabaila, P., & Vicendese, M. (2011). The Performance of a Two-Stage Analysis of ABAB/BABA Crossover Trials. arXiv:1101.5461v2 [math.ST].